Announcements Trials
Browse Landscape

Status

Approved for marketing 1

Sponsor Class

OTHER 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Osteosarcoma 6Renal Insufficiency 2Lymphoma 2Leukemia 2Water Intoxication 1Neoplasms 1Mucositis 1Hematologic Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1Acute Kidney Injury 1

Interventions

Cyclophosphamide 17pembrolizumab 12Doxorubicin 10fludarabine 7Irinotecan 7Blood Specimen Collection 7Temozolomide 6Gemcitabine 6Etoposide 6Radiotherapy 5Ifosfamide 5Carboplatin 5Albumin-Bound Paclitaxel 5tecogalan 4cemiplimab 4Vincristine 4Trabectedin 4Paclitaxel 4Nivolumab 4Filgrastim 4Drug Therapy 4Dexamethasone 4Bevacizumab 4pazopanib 3olaparib 3nilotinib 3dostarlimab 3aflibercept 3Therapeutics 3Taxes 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × glucarpidase × Sarcoma × Clear all
NCT00481559 2014-01-17

Treatment Protocol of Voraxaze for Patients Experiencing or at Risk of Methotrexate Toxicity

BTG International Inc.

Approved for marketing
LymphoidOther hematologic neoplasmSarcoma

Leukemia, Lymphoma, Neoplasms, Osteosarcoma, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡